So frustrating to see that it is just irrationally to have these prices.... i am not an experienced investor, but ADVM: 1. felt down from 10 to 4 in APR because of the bad side effects of the DME treatment; 2. has 400M cash and 40M debt only; at burn rate of 100M per year - 4years ahead are safe; 3. has only 100M shares, i.e. cash per share is 4$ today; 4. the 3y low is just under 3$; seems like now, at 2.3$ we are now at a ATL price; 5. they still have a working product 022, in progress; they also have a sold licence (see pipeline on their web).
What do I miss ladies and gentlemen? I got tired of averaging down...
q
Please see what Zacks said on June 25 when ADVM was $3.82. "Adverum Biotechnologies (ADVM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices." OMG, dropped to $2.26 today (-69%) in just 0ne month
J
this is one for your buy & hodl, set n forget portion of your portfolio. just a matter of time. #willing2wait
A
Great news! Buy more!!! Bio ETF just loaded with 3,5 mill more shares
P
Looking at recent exec changes, anyone know why this co. needs a chief marketing officer?
A
If they won’t use that DME anymore, means they take care of patients health. They should be up, not down.
q
No matter what, ADVM is absolutely undervalued. Market value ($331m) is lower than cash in hand ($404m). Stock price ($3.16) is lower than book value ($4.26). ADVM-22 is under investigating but this may not be a bad thing. I bought more and hold.
Awesome, an ideal "set and forget " just picked a boatload, thank you very much
D
It’s doing the limbo now🤦♂️
Bullish
M
Again, this stock is a hidden gem. Simply, NO one knows about it ! So much beaten down. Current SP is sitting now at 80% less than its IPO price. Cash on hand is more than its market cap. Great technology and very advanced pipeline. Annual market size is over $10B. All of this major discount is because one patient had a side-effect that is not sure if it is from the drug or from something else. Any little good news and it will triple. WAKE-UP guys !
u
$ADVM why insiders started to sell since last week? Do they know anything about the blind patient`s investigation progress or pre results?
A
400 mill cash on hand and only 30 mill debt! Why red????
What did Gene Editing do- took away the sails of several Gene Therapy Drug Companies with Hudred M to over Billion dollar pipelines- Why? Ask this before you sell your stock at a lower price than what you bought for- taking profits is fine with me:
2021 so far been quite bad year for trad gene tx..
The potential of the company is there, in the financial statements and the news. Just sit and wait!
Bullish
q
Only 3% higher than 52 wks low. ADVM has kept in $3.4 - $3.8 level for 2 months. Is there any news about AVDM-22 investigation? Is it time for ADVM to bounce back to $7?
M
NTLA is a gene-therapy company. ADVM is a gene-therapy company. Regeneron owns stake in both companies. NTLA will explode tomorrow (read today’s news). ADVM will EXPLODE soon.
f
hidden gem for $3.50 ! Julie Clark, M.D., Promoted to Chief Medical Officer As chief medical officer, Dr. Clark will be responsible for clinical strategy and implementation of clinical trials across all phases of development. !!!!!Dr. Clark brings 14 years of experience in clinical development programs and commercial launch initiatives for new therapies for ocular diseases, including !!!!!!Eylea® and BEOVU®!!!!!!. Previously, she !!!!!worked with Novartis!!!! over a five-year period in positions of increasing responsibility. As lead medical director – retina, !!!!!!she was responsible for the Phase 3b clinical trial for BEOVU®!!!!!!and served as medical lead for cross-functional team initiatives for product launch. Earlier, she was medical director, U.S. medical affairs for ThromboGenics, where she supported the Jetrea® launch and late-stage clinical studies. Previously,!!! she worked with Regeneron Pharmaceuticals, Inc!!!!!!, where as associate director, medical affairs – ophthalmology she supported the !!!!!clinical development and commercial launch of Eylea®!!!!!. Before Regeneron, she worked with ISTA Pharmaceuticals as medical affairs product director and helped align strategy and communications for Xibrom®/Bromday®, Bepreve®, Istalol®, Vitrase®. Dr. Clark earned an M.D. from Wake Forest University School of Medicine and a B.S. in Biology from Wake Forest University. In addition, she holds an M.S. in Biotechnology from the Center for Biotechnology Education and Advanced Biotechnology Studies from Johns Hopkins University.
1. felt down from 10 to 4 in APR because of the bad side effects of the DME treatment;
2. has 400M cash and 40M debt only; at burn rate of 100M per year - 4years ahead are safe;
3. has only 100M shares, i.e. cash per share is 4$ today;
4. the 3y low is just under 3$; seems like now, at 2.3$ we are now at a ATL price;
5. they still have a working product 022, in progress; they also have a sold licence (see pipeline on their web).
What do I miss ladies and gentlemen? I got tired of averaging down...
Maintains Chardan Capital Neutral USD 5 » USD 3
Downgraded by Goldman Sachs USD 2.51
Downgrades Cantor Fitzgerald Neutral USD 23 » USD 3
Maintains SVB Leerink Market Perform USD 5 » USD 2
why insiders started to sell since last week? Do they know anything about the blind patient`s investigation progress or pre results?
2021 so far been quite bad year for trad gene tx..
-from 52 week high (VYGR ADVM both -EV)
$VYGR -72%
$ADVM -85%
$QURE -43%
$BLUE -54%
$avro -57%
$PASG -56%
$GBIO -53%
$SRPT -59%
Concerned about revenue drop:
2017 = 1800
2018 = 1600
2019 = 250
2020 = 0
Market cap : $359M
Price/book : $0.87
👀
ADVM is a gene-therapy company.
Regeneron owns stake in both companies.
NTLA will explode tomorrow (read today’s news).
ADVM will EXPLODE soon.
As chief medical officer, Dr. Clark will be responsible for clinical strategy and implementation of clinical trials across all phases of development. !!!!!Dr. Clark brings 14 years of experience in clinical development programs and commercial launch initiatives for new therapies for ocular diseases, including !!!!!!Eylea® and BEOVU®!!!!!!. Previously, she !!!!!worked with Novartis!!!! over a five-year period in positions of increasing responsibility. As lead medical director – retina, !!!!!!she was responsible for the Phase 3b clinical trial for BEOVU®!!!!!!and served as medical lead for cross-functional team initiatives for product launch. Earlier, she was medical director, U.S. medical affairs for ThromboGenics, where she supported the Jetrea® launch and late-stage clinical studies. Previously,!!! she worked with Regeneron Pharmaceuticals, Inc!!!!!!, where as associate director, medical affairs – ophthalmology she supported the !!!!!clinical development and commercial launch of Eylea®!!!!!. Before Regeneron, she worked with ISTA Pharmaceuticals as medical affairs product director and helped align strategy and communications for Xibrom®/Bromday®, Bepreve®, Istalol®, Vitrase®. Dr. Clark earned an M.D. from Wake Forest University School of Medicine and a B.S. in Biology from Wake Forest University. In addition, she holds an M.S. in Biotechnology from the Center for Biotechnology Education and Advanced Biotechnology Studies from Johns Hopkins University.